ArticleUnited European gastroenterology journal2018
A meta-analysis on the cardiac safety profile of domperidone compared to metoclopramide.
Article in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 50 citations in OpenAlex.
- Machine learning-based prediction of herbal medicine response in functional dyspepsia: protocol for a randomized, assessor-blinded, multicenter trial.Frontiers in medicine · 2026Article
- Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma.Cancer cell international · 2024Article
- Pilot Study on QTc Interval in Dogs Treated with Domperidone.Veterinary sciences · 2024Article
- A real-world retrospective study of omeprazole-domperidone combination in managing acid peptic disease with PRoton-pump Inhibitors in patients with type 2 DiabEtes mellitus (PRIDE-2).Drugs in context · 2023Article
- Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Journal of clinical medicine · 2022Review
- A fatal case of repeated ventricular fibrillation due to torsade de pointes following repeated administration of metoclopramide.Clinical case reports · 2022Article
- Non-pharmacological management of pediatric functional abdominal pain disorders: Current evidence and future perspectives.World journal of clinical pediatrics · 2022Review
- Cardiovascular Safety of Metoclopramide Compared to Domperidone: A Population-Based Cohort Study.Journal of the Canadian Association of Gastroenterology · 2021Article
- Association between Domperidone Administered via Feeding Tube and Feeding Success in Critically Ill Patients with Enteral Feeding Intolerance.Journal of personalized medicine · 2021Article
- Effect of domperidone, ondansetron, olanzapine-containing antiemetic regimen on QTScientific reports · 2021Observational
- Nausea and Vomiting: a Palliative Care Imperative.Current oncology reports · 2020Review
- Diabetic Gastroparesis: Perspectives From a Patient and Health Care Providers.Journal of patient-centered research and reviews · 2019Review
- Pathophysiology and management of diabetic gastroenteropathy.Therapeutic advances in gastroenterology · 2019Review
- Perioperative pain management in COVID-19 patients: Considerations and recommendations by the Saudi Anesthesia Society (SAS) and Saudi Society of Pain Medicine (SSPM).Saudi journal of anaesthesiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis meta-analysis aimed to assess the cardiac safety profile of domperidone treatment for the risk of cardiovascular (CV) event and QT prolongation.
methodsData from nine studies involving 101,155 patients were used for the analysis of CV event risk, while data from eight studies involving 390 patients were used for the analysis of QT prolongation risk.
resultsMeta-analysis findings suggested a significant increase in CV risk under domperidone as compared to no treatment for domperidone doses of >30 mg/day (OR: 3.14, 95% CI, 1.191 to 8.304,
conclusionsThe present meta-analysis indicates that domperidone treatment may not be associated with an overall CV event risk increase at doses ≤30 mg/day and does not result in QT prolongation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.